"The Indiana Hemophilia and Thrombosis Center (IHTC) provides advanced care for adults, teens, and children with rare blood disorders. We treat patients with hemophilia, thrombosis, von Willebrand disease, sickle cell disease, and other bleeding and clotting disorders—including rare conditions. Additional Blood Disorders: • Autoimmune Hemolytic Anemia • Chronic Neutropenia • G6PD • Hemochromatosis • Hereditary Spherocytosis • Heredity Hemorrhagic Telangiectasia (HHT) • Hemangioma, Vascular and Lymphatic Malformations (HVLM) • Myelodysplastic Syndromes • Qualitative Platelet Disorders • Thalassemia Specialty Clinics: • Joint Health Clinic • Sickle Cell Well Clinic • HVLM Clinic • HTT Center • Girls & Women Only Clinic"

During the past decade, Indiana Hemophilia and Thrombosis Center conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 19 clinical trials were completed, i.e. on average, 57.6% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 11 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Indiana Hemophilia and Thrombosis Center" #1 sponsor was "Baxalta now part of Shire" with 11 trials, followed by "American Thrombosis and Hemostasis Network" with 6 trials sponsored, "Indiana Hemophilia &Thrombosis Center, Inc." with 3 trials sponsored, "Prometic Biotherapeutics, Inc." with 3 trials sponsored and "Agios Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Indiana Hemophilia and Thrombosis Center" #1 collaborator was "Genentech, Inc." with 4 trials as a collaborator, "Swedish Orphan Biovitrum" with 3 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 2 trials as a collaborator, "Bioverativ Therapeutics Inc." with 2 trials as a collaborator and "CSL Behring" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Indiana Hemophilia and Thrombosis Center" are "Hemophilia A" (15 trials), "Hemophilia B" (10 trials), "Von Willebrand Disease" (4 trials), "Hemophilia" (3 trials) and "Hypoplasminogenemia" (3 trials). Many other conditions were trialed in "Indiana Hemophilia and Thrombosis Center" in a lesser frequency.

Most popular intervention types in "Indiana Hemophilia and Thrombosis Center" are "Biological" (22 trials), "Drug" (22 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Emicizumab" (5 trials), "Antihemophilic factor, recombinant, manufactured protein-free" (3 trials), "AG-348" (2 trials), "Antihemophilic Factor (Recombinant)" (2 trials) and "IB1001" (2 trials). Other intervention names were less common.

The vast majority of trials in "Indiana Hemophilia and Thrombosis Center" are 39 trials for "All" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Indiana Hemophilia and Thrombosis Center". undefined are not yet recruiting, 10 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Indiana Hemophilia and Thrombosis Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Indiana Hemophilia and Thrombosis Center, 6 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".